Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study | Synapse
Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study
Key Points
The aim was to evaluate the safety and tolerability of oral islatravir as pre-exposure prophylaxis in specific populations.
Conducted a randomized Phase 3 trial (IMPOWER-24)
Included cisgender men and transgender women
Assessed safety and tolerability of monthly islatravir
Islatravir was well-tolerated overall
Decreases in total lymphocytes were noted with islatravir use
Primary efficacy objectives were not analyzed due to early study termination
Abstract
Islatravir qm was generally well-tolerated; decreases in total lymphocytes were observed with islatravir. Original primary efficacy objectives were not assessed due to early study stoppage.